Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.

doi:10.1007/978-1-4615-0081-0_11

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.

Advances in experimental medicine and biology - 1 Jan 2003

Sattler Martin, Scheijen Blanca, Weisberg Ellen, Griffin James D

Abstract excerpt

Tyrosine kinases are commonly mutated and activated in both acute and chronic myeloid leukemias. Here, we review the functions, signaling activities, mechanism of transformation, and therapeutic targeting of two prototypic tyrosine kinase oncogenes, BCR-ABL and FLT3, associated with chronic myeloid leukemia (CML) and acute myeloid leukemia (AML), respectively. BCR-ABL is generated by the Philadelphia chromosome...

Topics

Animals
Benzamides
Binding Sites
Clinical Trials as Topic
Enzyme Inhibitors
Fusion Proteins, bcr-abl
Humans
Imatinib Mesylate
Leukemia
Leukemia, Myeloid
Mice

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Mutation

Piperazines

Protein Structure, Tertiary

Protein-Tyrosine Kinases

Proto-Oncogene Proteins

Pyrimidines

Receptor Protein-Tyrosine Kinases

Source

Open in PubMed

Identifiers

PMID: 12908554
DOI: 10.1007/978-1-4615-0081-0_11

Genes

BCR
FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.PMID 12908554Read ↗

Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias.Semantic proximity Read ↗

Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.Semantic proximity Read ↗

Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.Semantic proximity Read ↗

BCR-ABL-negative chronic myeloid leukemia.Semantic proximity Read ↗

Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.Semantic proximity Read ↗

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapySemantic proximity Read ↗

Molecular genetics of human leukemias: new insights into therapy.Semantic proximity Read ↗

BCR-ABL: The molecular mastermind behind chronic myeloid leukemiaSemantic proximity Read ↗

Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human LeukemiaSemantic proximity Read ↗

Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.Semantic proximity Read ↗

Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

Targeted signal transduction therapies in myeloid malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.